David König

机构：Royal Marsden NHS Foundation Trust, University of Basel, University Hospital of Basel, Department of Biomedicine Basel · ORCID：0000-0003-3559-6855

发表论文 96 篇 · 总被引 712 次 · h-index 13

代表论文

• Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours (2024 · Nature · 被引 125)
• Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy (2024 · European Journal of Cancer · 被引 35)
• MTAP as an emerging biomarker in thoracic malignancies (2024 · Lung Cancer · 被引 25)
• Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma (2024 · Immuno-Oncology Technology · 被引 13)
• ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC (2025 · Lung Cancer · 被引 12)
• MTAP Expression by Immunohistochemistry: A Novel Biomarker in NSCLC (2025 · Journal of Thoracic Oncology · 被引 9)